What is the current Recombinant Parvovirus Antigens market size?

The Recombinant Parvovirus Antigens market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Recombinant Parvovirus Antigens market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Recombinant Parvovirus Antigens market?

Key drivers include rising prevalence of parvovirus infections and growing awareness of recombinant antigens.

What are the major challenges facing the Recombinant Parvovirus Antigens market?

Challenges include high development costs and stringent regulatory requirements.

Which regions are the leaders in the Recombinant Parvovirus Antigens market?

North America and Europe are the leading regions due to advanced healthcare infrastructure.

Who are the top companies in the Recombinant Parvovirus Antigens market?

Top companies include pharmaceutical giants and biotechnology firms investing in recombinant antigen research.

What are the future opportunities in the Recombinant Parvovirus Antigens market?

Future opportunities include emerging markets and increasing adoption of recombinant antigens in diagnostics.

How will technology impact the Recombinant Parvovirus Antigens market?

Advances in genetic engineering and biotechnology will drive innovation and growth in the market.

What is the current regulatory landscape for the Recombinant Parvovirus Antigens market?

The regulatory landscape is governed by strict guidelines and protocols to ensure safety and efficacy.

What is the future outlook for the Recombinant Parvovirus Antigens market?

The future outlook is positive, with increasing demand and growing investment in research and development.

Which Companies Lead the Recombinant Parvovirus Antigens Market in 2026?

Recombinant Parvovirus Antigens by Application (Hospital, Diagnostic Laboratory, Others), by Types (Antigen NS1, Antigen VP1, Antigen VP2, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $850 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $850 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Recombinant Parvovirus Antigens Market Size | CAGR 12.8 Forecast 2033

Which Companies Lead the Recombinant Parvovirus Antigens Market in 2026?

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $850 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $850 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Recombinant Parvovirus Antigens Market Overview

The Recombinant Parvovirus Antigens market refers to the industry involved in the development and distribution of recombinant parvovirus antigens, which are used in various applications such as diagnostics, research, and vaccine development. As the global healthcare industry continues to evolve, the Recombinant Parvovirus Antigens market size is expected to experience significant growth, driven by increasing demand for effective diagnostic tools and vaccines. The growth outlook for the Recombinant Parvovirus Antigens market is promising, with a projected market forecast of $1.3 billion by 2026 and an expected compound annual growth rate (CAGR) of 8.5% during the forecast period from 2026 to 2033, driven by industry expansion and advancements in technology.

Loading chart…

Key forces shaping the Recombinant Parvovirus Antigens industry include technology shifts, such as advancements in recombinant DNA technology, regulations governing the use of antigens in diagnostics and vaccine development, and consumer behavior, driven by increasing awareness of the importance of diagnostics and vaccinations. The largest region for the Recombinant Parvovirus Antigens market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing demand for diagnostic tools and vaccines in emerging economies. As the market continues to evolve, it is essential for industry players to stay informed about the latest trends and developments to remain competitive.

Report Overview

Report Attribute	Details
Market size value in 2025	850.00 million
Revenue forecast in 2033	2.23 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ELlTechGroup; Diesse Diagnostica Senese; R-Biopharm AG; Zoetis; altona Diagnostics GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Recombinant Parvovirus Antigens market is poised for significant growth, driven by various factors. Understanding the market dynamics is crucial for stakeholders to navigate this complex landscape.

Growth Drivers2 items

Increasing demand for Recombinant Parvovirus Antigens in the pharmaceutical industry, driven by the need for effective diagnostic tools and treatments for parvovirus infections, is expected to propel the Recombinant Parvovirus Antigens market size.

Advances in recombinant DNA technology and protein expression systems have improved the production efficiency and yield of recombinant parvovirus antigens, contributing to the growth forecast of the market.

Restraints2 items

Stringent regulatory requirements and rigorous testing protocols for recombinant parvovirus antigens may hinder the growth of the Recombinant Parvovirus Antigens market, as companies may struggle to meet these standards.

High production costs associated with recombinant parvovirus antigens, including the cost of raw materials, equipment, and labor, may limit the adoption of these products, particularly in price-sensitive markets.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America offer significant growth opportunities for the Recombinant Parvovirus Antigens market, driven by increasing demand for diagnostic tools and treatments for parvovirus infections in these regions.

The development of novel applications for recombinant parvovirus antigens, such as in vaccine development and cancer therapy, is expected to expand the market size and drive growth in the Recombinant Parvovirus Antigens market.

Challenges2 items

Intense competition in the Recombinant Parvovirus Antigens market may lead to pricing pressure and reduced profit margins for companies, making it challenging to sustain growth and invest in research and development.

Ensuring the stability and consistency of recombinant parvovirus antigens during storage and transportation is a significant challenge, as these products are sensitive to temperature, humidity, and other environmental factors, which can impact the growth forecast of the market.

Market Segmentation

Loading chart…

The Recombinant Parvovirus Antigens market can be segmented based on application, which includes various fields such as veterinary medicine, research and development, and diagnostics. The application segment contributes significantly to the overall Recombinant Parvovirus Antigens market size, with each sub-segment having its own unique requirements and growth prospects. Understanding the Recombinant Parvovirus Antigens segmentation by application is crucial for market players to develop targeted strategies and capitalize on emerging opportunities.

In terms of types, the Recombinant Parvovirus Antigens market encompasses various subtypes, including [object Object] and [object Object]. Each subtype has distinct characteristics, advantages, and limitations, which influence their adoption and market share. Analyzing the market taxonomy of Recombinant Parvovirus Antigens by types provides valuable insights into the competitive landscape, market trends, and future outlook. By examining the types segment, industry stakeholders can identify areas for innovation, investment, and growth, ultimately driving the expansion of the Recombinant Parvovirus Antigens market.

Recombinant Parvovirus Antigens Segmentation Breakdown9 items

Application

Hospital

Diagnostic Laboratory

Others

Types

Antigen NS1

Antigen VP1

Antigen VP2

Others

Regional Insights

Loading chart…

The Recombinant Parvovirus Antigens market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 35% of the global market, driven by factors such as high adoption rates, favorable policies, and significant investments in research and development. Europe is the second-largest region, with a share of around 25%, driven by a mature ecosystem, high infrastructure quality, and a large patient population.

The fastest-growing region is expected to be Asia Pacific, with a growth rate driven by increasing demographics, rising infrastructure quality, and growing demand for innovative treatments. Latin America and Middle East & Africa are also expected to experience significant growth, driven by improving ecosystem maturity, increasing adoption rates, and government policies supporting the development of the Recombinant Parvovirus Antigens market.

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, significant investments

Europe: mature ecosystem, high infrastructure quality, large patient population

Asia Pacific: increasing demographics, rising infrastructure quality, growing demand

Latin America: improving ecosystem maturity, increasing adoption rates, government policies

Middle East & Africa: growing demand, improving infrastructure, government support

Competitive Landscape

The Recombinant Parvovirus Antigens market exhibits a moderately consolidated structure, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Recombinant Parvovirus Antigens competitive landscape is driven by the need for companies to differentiate themselves through these levers. Global players tend to focus on product innovation and regulatory approvals, while local companies often prioritize distribution and pricing strategies.

Companies in this market employ various strategies to gain a competitive edge, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to address these challenges and maintain their market position.

ELlTechGroup: regional expansion

Diesse Diagnostica Senese: premium pricing

R-Biopharm AG: OEM tie-ups

Zoetis: innovation pipeline

altona Diagnostics GmbH: local manufacturing

Other players: vertical integration

Key Recombinant Parvovirus Antigens Companies5 items

ELlTechGroup

Diesse Diagnostica Senese

R-Biopharm AG

Zoetis

altona Diagnostics GmbH

Market Ecosystem

The Recombinant Parvovirus Antigens ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of recombinant parvovirus antigens, which are used in various applications such as research, diagnostics, and vaccine development. Understanding the Recombinant Parvovirus Antigens ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — provide essential components

Technology providers — develop manufacturing technologies

OEMs/manufacturers — produce recombinant parvovirus antigens

Distributors/channel partners — facilitate product distribution

Service providers/after-sales — offer support and maintenance

End users/buyers — utilize recombinant parvovirus antigens

Regulators/standards bodies — establish guidelines and standards

The flow of value in the Recombinant Parvovirus Antigens ecosystem is influenced by various control points, including regulatory approvals, quality standards, and supply chain dependencies. Dependency risks, such as input constraints and standards, can impact the adoption of recombinant parvovirus antigens. Moreover, switching costs, partnerships, and interoperability requirements can affect the relationships between ecosystem participants. The Recombinant Parvovirus Antigens ecosystem may differ by region due to varying regulatory frameworks, market demand, and competitive landscapes.

Recent Industry Insights

The Recombinant Parvovirus Antigens industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed between key players to enhance research and development capabilities, while mergers and acquisitions have led to consolidation and expansion of product portfolios. Recently, several companies have launched innovative products and technologies, further driving growth in the market. Additionally, regulatory changes have paved the way for increased adoption of recombinant parvovirus antigens in various applications. A shift in consumer and enterprise trends towards more effective and efficient solutions has also been observed, with funding rounds and expansions supporting the development of new and improved products.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Recombinant Parvovirus Antigens market. The market attractiveness is high due to increasing demand for diagnostic and therapeutic applications. The competitive intensity is moderate, with key players investing in research and development to improve product portfolios. The long-term outlook for the Recombinant Parvovirus Antigens market outlook is positive, driven by advancements in technology and growing awareness about parvovirus diseases.

The innovation landscape is evolving, with a focus on developing more effective and safer products. The demand–supply balance is stable, with manufacturers working to meet the rising demand. However, key risk factors such as regulatory changes and supply chain disruptions may impact the market. Overall, the Recombinant Parvovirus Antigens market is expected to experience steady growth, driven by its potential in diagnostic and therapeutic applications.

11 items

1. Executive Summary

2. Recombinant Parvovirus Antigens Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Recombinant Parvovirus Antigens Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Recombinant Parvovirus Antigens Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Diagnostic Laboratory

6.1.3. Others

6.2. Global Recombinant Parvovirus Antigens Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antigen NS1

6.2.2. Antigen VP1

6.2.3. Antigen VP2

6.2.4. Others

6.3. Global Recombinant Parvovirus Antigens Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Recombinant Parvovirus Antigens Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Recombinant Parvovirus Antigens Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Recombinant Parvovirus Antigens Market Competition by Key Manufacturers

8.1. Global Recombinant Parvovirus Antigens Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Recombinant Parvovirus Antigens: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. ELlTechGroup

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Diesse Diagnostica Senese

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. R-Biopharm AG

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Zoetis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. altona Diagnostics GmbH

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Recombinant Parvovirus Antigens Market

Figure 4: Global Recombinant Parvovirus Antigens Market: Drivers

Figure 5: Global Recombinant Parvovirus Antigens Market: Challenges

Figure 6: Global Recombinant Parvovirus Antigens Market: Trends

Figure 7: Global Recombinant Parvovirus Antigens Market: Opportunity

Figure 8: Global Recombinant Parvovirus Antigens Market: Restraint

Figure 9: Global Recombinant Parvovirus Antigens Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Recombinant Parvovirus Antigens Market Value (USD Million) By Region

Figure 15: Global Recombinant Parvovirus Antigens Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Recombinant Parvovirus Antigens Market Value (USD Million) By Region

Figure 23: Global Recombinant Parvovirus Antigens Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Recombinant Parvovirus Antigens Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Recombinant Parvovirus Antigens Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Recombinant Parvovirus Antigens Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Recombinant Parvovirus Antigens Market Value (USD Million) By Region

Table 10: Global Recombinant Parvovirus Antigens Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Recombinant Parvovirus Antigens Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Recombinant Parvovirus Antigens Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Recombinant Parvovirus Antigens Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: ELlTechGroup Basic Information And Sales Area

Table 31: ELlTechGroup. Products Portfolio

Table 32: Diesse Diagnostica Senese Basic Information And Sales Area

Table 33: Diesse Diagnostica Senese. Products Portfolio

Table 34: R-Biopharm AG Basic Information And Sales Area

Table 35: R-Biopharm AG. Products Portfolio

Table 36: Zoetis Basic Information And Sales Area

Table 37: Zoetis. Products Portfolio

Table 38: altona Diagnostics GmbH Basic Information And Sales Area

Table 39: altona Diagnostics GmbH. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Recombinant Parvovirus Antigens Market Value (USD Million) By Region

Table 45: Global Recombinant Parvovirus Antigens Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Recombinant Parvovirus Antigens Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	850.00 million
Revenue forecast in 2033	2.23 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ELlTechGroup; Diesse Diagnostica Senese; R-Biopharm AG; Zoetis; altona Diagnostics GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options